期刊文献+

雄激素非依赖性前列腺癌介入治疗的临床观察(附23例报告)

Internal iliac artery chemotherapy for the treatment of androgen-independent prostate cancer
下载PDF
导出
摘要 目的:观察经髂内动脉灌注化疗治疗雄激素非依赖性前列腺癌(Androgen-independent prostate cancer,AIPC)的临床疗效。方法:将38例已确诊为AIPC患者按治疗时间先后随机分为介入治疗组与对照组,其中介入治疗组23例在内分泌治疗(药物加手术去势),同时行双侧髂内动脉定期灌注化疗;对照组15例采用内分泌治疗,观察并比较二者疗效。结果:介入治疗组临床症状明显减轻,最大尿流率在治疗后6个月明显改善,与对照组比较差异有统计学意义,经2年随访,介入治疗组与对照组总有效率分别为65.2%与26.7%,二者相比差异有统计学意义(P<0.05)。结论:经双侧髂内动脉灌注化疗治疗AIPC疗效肯定,可显著改善患者的临床症状与生活质量。 Objective:To observe the effects of bilateral internal iliac artery infusion of chemotherapeutic agents for the treatment of androgen-independent prostate cancer (AIPC). Methods: A total of 38 cases of patients with AIPC were randomly divided into treatment group and control group. The patients in treatment group (23 cases) were treated with androgen deprivation therapy and regular internal iliac artery infusion of chemotherapeutic agents, while the patients in control group (15 cases) were only treated with androgen deprivation. The efficiencies of the two groups were compared and analyzed when the therapies were completed. Results:The clinical symptoms and maximum flow rates of treatment group were improved rapidly 6 months later. After 2 years follow-up, the total improvement rate of the treatment group and control group were 65.2 % and 26.7 % respectively. The difference was of significance(P;0.05). Conelt;ions: The treatment of AIPC with bilateral internal iliac artery infusion of chemotherapeutic agents is effective, it can meliorate the quality of life and alleviate symptoms of AIPC patients.
出处 《临床泌尿外科杂志》 2007年第9期647-650,共4页 Journal of Clinical Urology
关键词 前列腺癌 髂内动脉 灌注化疗 预后 Prostate cancer Internal iliac artery Infusion therapy Prognosis
  • 相关文献

参考文献8

  • 1高江平,洪宝发.雄激素非依赖性前列腺癌的治疗策略[J].中华泌尿外科杂志,2005,26(4):286-287. 被引量:7
  • 2贺松琴,曹广文.雄激素非依赖性前列腺癌发生的分子机制[J].国外医学(泌尿系统分册),2005,25(6):811-815. 被引量:5
  • 3沈华锋,郑祥毅,谢立平.雄激素受体与激素非依赖性前列腺癌[J].国外医学(泌尿系统分册),2005,25(4):461-465. 被引量:4
  • 4Buhley G J, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group[J]. J Clin Oncol, 1999, 17: 3461-3467.
  • 5Ryan C J, Small E J. Role of secondary hormonal therapy in the management of recurrent disease[J]. Urology, 2003,62(Suppl 6B): 87-94.
  • 6Saad F, Gleason D M, Murry R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma [J]. J Natl Cancer Inst,2002,94:1458-1468.
  • 7Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline[J]. J Urol, 2000,164:1248-1253.
  • 8Patel P, Ashdown D, James N, et al. Is gene therapy the answer for prostate cancer [J]. Prostate Cancer Prostatic Dis, 2004,7(Suppl:s):14-19.

二级参考文献45

  • 1Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med,2004,10:33 - 9.
  • 2Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res,2004,64(2):765-71.
  • 3Steketee K, Timmerman L,Ziel-van der Made AC, et al. ligand responsiveness of and rogen receptor mutants obtained by random amino acid substituti Broadened on of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer, 2002,100(3):309-17.
  • 4Masiello D, Chen SY, Xu Y, et al. Recruitment of beta - catenin by wild-type or mutant androgen receptors correlates with ligand - stimulated growth of prostate cancer cells. Mol Endocrinol, 2004, 18(10):2388-401.
  • 5Song LN, Coghlan M, Gelmarn EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol, 2004,18(1):70 - 85.
  • 6Wang Q, Udayakumar TS, Vasaitis TS, et al. Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen - dependent transcriptional hyperactivity in prostate cancer cells.J Biol Chem,2004,279(17): 17319 - 28.
  • 7Park J, Irvine R, Buchanan G, et al. Breast cancer susceptibility gene 1(BRCA1) is a coactivator of the androgen receptor. Cancer Res, 2000,60:5946 - 9.
  • 8Shin S, Verma IM. BRCA2 cooperates with histone acetyltransferases in androgen receptor - mediated transcription. Proc Natl Acad Sci USA,2003,100(12):7201 - 6.
  • 9Mestayer C,Blanchere M,Jaubert F,et al. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines.Prostate,2003,56(3): 192 - 200.
  • 10Guerrero- Santoro J, Yang L, Stallcup MR, et al. Distinct LIM domains of Hic- 5/ARA55 are required for nuclear matrix targeting and glucocorticoid receptor binding and coactivation. J Cell Biochem, 2004, 92(4):810-9.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部